Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.

Leerink Partners reiterated their market perform rating on shares of 2seventy bio (NASDAQ:TSVT – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. The brokerage ...

Investorideas ( ), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for 2seventy bio ...

Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B. Check out the portfolio's top holdings and notable stake ...

Over the last 7 days, the United States market has experienced a 3.7% decline, although it has shown a 6.9% increase over the past year with earnings projected to grow by 14% annually. In this context ...

The former SVP of global sales and the leader in sales engineering from Klaviyo have emerged from stealth with a new startup backed by Klaviyo founders, Asymmetric Capital Partners and Underscore VC.

CL King analyst Andrew Wolf upgraded United Natural Foods (UNFI) to Buy from Neutral with a $33 price target Q2 results “beat solidly” and ...

Barclays analyst Tim Long raised the firm’s price target on Ciena (CIEN) to $100 from $97 and keeps an Overweight rating on the shares. The ...

Based on internal projections for demand, the two companies have approved about $150 million in additional investments to ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders ...